IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy.
Hatzivassiliou G,
Miller I,
Takizawa J,
Palanisamy N,
Rao PH,
Iida S,
Tagawa S,
Taniwaki M,
Russo J,
Neri A,
Cattoretti G,
Clynes R,
Mendelsohn C,
Chaganti RS,
Dalla-Favera R.
Institute of Cancer Genetics, Columbia University, New York, NY 10032, USA.
Abnormalities of chromosome 1q21 are common in B cell malignancies, but their target genes are largely unknown. By cloning the breakpoints of a (1;14) (q21;q32) chromosomal translocation in a myeloma cell line, we have identified two novel genes, IRTA1 and IRTA2, encoding cell surface receptors homologous to the Fc and inhibitory receptor families. Both genes are selectively expressed in mature B cells: IRTA1 in marginal zone B cells and IRTA2 in centrocytes, marginal zone B cells, and immunoblasts. As a result of the t(1;14), IRTA1 is fused to the immunoglobulin Calpha domain to produce a chimeric IRTA1/Calpha fusion protein. In tumor cell lines with 1q21 abnormalities, IRTA2 expression is deregulated. Thus, IRTA1 and IRTA2 are novel immunoreceptors implicated in B cell development and lymphomagenesis.
PMID: 11290337 [PubMed - indexed for MEDLINE]